BioCardia (NASDAQ:BCDA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BioCardia (NASDAQ:BCDA) from a sell rating to a hold rating in a research report sent to investors on Saturday.

BCDA has been the subject of a number of other research reports. Zacks Research raised shares of BioCardia from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a research report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research note on Tuesday, June 9th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $25.00.

BioCardia Trading Down 3.5%

NASDAQ:BCDA opened at $0.94 on Friday. The stock has a 50 day simple moving average of $0.94 and a 200 day simple moving average of $1.07. The stock has a market cap of $10.70 million, a P/E ratio of -1.47 and a beta of 0.49. BioCardia has a 1-year low of $0.75 and a 1-year high of $2.29.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. As a group, sell-side analysts forecast that BioCardia will post -0.71 EPS for the current year.

Insider Buying and Selling

In related news, Director Simon H. Stertzer acquired 70,200 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was purchased at an average cost of $0.92 per share, with a total value of $64,584.00. Following the acquisition, the director directly owned 127,338 shares of the company’s stock, valued at approximately $117,150.96. The trade was a 122.86% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders acquired 136,800 shares of company stock worth $128,324. 17.40% of the stock is owned by company insiders.

Institutional Trading of BioCardia

Several large investors have recently modified their holdings of BCDA. Geode Capital Management LLC increased its position in shares of BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after purchasing an additional 27,263 shares during the period. DRW Securities LLC bought a new stake in BioCardia during the fourth quarter worth about $72,000. Finally, Cetera Investment Advisers acquired a new stake in BioCardia during the second quarter worth about $40,000. 20.57% of the stock is owned by institutional investors and hedge funds.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.